Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 4/20 | 0.84 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.84 |
| ▸ | TBXAS1 | P24557 | 11/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 11/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771846 | 1.00 | PTGIR (0.84) | PTGIRPTGDRTBXAS1TBXA2RMEN1 | |
| SCHEMBL32681969 | 1.00 | PTGIR (0.84) | PTGIRPTGDRTBXAS1TBXA2RMEN1 | |
| SCHEMBL3771841 | 1.00 | PTGIR (0.84) | PTGIRPTGDRTBXAS1TBXA2RMEN1 | |
| SCHEMBL9014475 | 0.92 | PTGIR (0.70) | PTGIRPTGDRTBXAS1TBXA2RMEN1 | |
| SCHEMBL9014484 | 0.92 | PTGIR (0.70) | PTGIRPTGDRTBXAS1TBXA2RMEN1 | |
| SCHEMBL9014255 | 0.92 | PTGIR (0.89) | PTGIRPTGDRTBXAS1TBXA2RALDH1A1 | |
| SCHEMBL9014259 | 0.92 | PTGIR (0.89) | PTGIRPTGDRTBXAS1TBXA2RALDH1A1 | |
| SCHEMBL16938456 | 0.92 | PTGIR (0.70) | PTGIRPTGDRTBXAS1TBXA2RMEN1 | |
| SCHEMBL9974582 | 0.89 | PTGIR (0.67) | PTGIRPTGDRTBXAS1TBXA2RALDH1A1 | |
| SCHEMBL9014532 | 0.88 | PTGIR (0.68) | PTGIRPTGDRTBXAS1TBXA2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080299089-A1 | ENDOGENEOUS REPAIR FACTOR PRODUCTION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-04 | — | — | US | claimed |
| US-20060069018-A1 | Endogenous repair factor production promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-30 | — | — | US | claimed |
| EP-1563846-A1 | ENDOGENOUS REPAIR FACTOR PRODUCTION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-17 | — | — | EP | claimed |
| EP-0581187-B1 | Oxime derivatives | ONO PHARMACEUTICAL CO (JP) | 1996-12-04 | — | — | EP | claimed |
| US-5480998-A | Oxime derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | claimed |
| EP-0581187-A1 | Oxime derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-02-02 | — | — | EP | claimed |
| EP-2913047-B1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | CARDIO INCORPORATED (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-2913047-B1 | PULMONARY DISEASE-SPECIFIC THERAPEUTIC AGENT | CARDIO INCORPORATED (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-2898902-B1 | ADVANCED HEART FAILURE TREATMENT MATERIAL AS MYOCARDIAL/CARDIOVASCULAR REGENERATION DEVICE | UNIV OSAKA (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-9968716-B2 | Drug-eluting stent graft | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9968716-B2 | Drug-eluting stent graft | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9968716-B2 | Drug-eluting stent graft | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9597436-B2 | Advanced heart failure treatment material as myocardial/cardiovascular regeneration device | OSAKA UNIVERSITY (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20060069018-A1 | Endogenous repair factor production promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1563846-A1 | ENDOGENOUS REPAIR FACTOR PRODUCTION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-0581187-B1 | Oxime derivatives | ONO PHARMACEUTICAL CO (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-5480998-A | Oxime derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0581187-A1 | Oxime derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299089-A1 | ENDOGENEOUS REPAIR FACTOR PRODUCTION PROMOTERS | PTGER4, PTGIR, PTGER1 | PTGIR 2/4885PTGDR 14/4885TBXAS1 30/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | PTGIR 4383/4885PTGDR 3360/4885TBXAS1 3463/4885 |
| US-20060069018-A1 | Endogenous repair factor production promoters | PTGIR, PTGER4, PTGER1 | PTGIR 1/4885PTGDR 12/4885TBXAS1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.